Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma

John W. Nelson, A. Paiman Ghafoori, Christopher G. Willett, Douglas Tyler, Theodore N. Pappas, Bryan M. Clary, Herbert I. Hurwitz, Johanna C. Bendell, Michael A. Morse, Robert W. Clough, Brian G. Czito

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Purpose: Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. Methods and Materials: A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors. Results: Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age ≤60 years and perineural involvement adversely affected survival on univariate analysis. Patients undergoing R0 resection had a significantly improved rate of local control but no survival advantage. Despite having more advanced disease at presentation, patients treated neoadjuvantly had a longer survival (5-year survival 53% vs. 23%, p = 0.16) and similar rates of Grade 2-3 surgical morbidity (16% vs. 33%, p = 0.24) compared with those treated in the postoperative setting. Conclusion: These study results suggest a possible local control benefit from chemoradiotherapy combined with surgery in patients with advanced, resected biliary cancer. Furthermore, our results suggest that a treatment strategy that includes preoperative chemoradiotherapy might result in improved tumor resectability with similar surgical morbidity compared with patients treated postoperatively, as well as potentially improved survival outcomes. Distant failure remains a significant failure pattern, suggesting the need for more effective systemic therapy.

Original languageEnglish (US)
Pages (from-to)148-153
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume73
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Cholangiocarcinoma
Chemoradiotherapy
Survival
radiation therapy
chemotherapy
Radiotherapy
Biliary Tract Neoplasms
Morbidity
Drug Therapy
Adjuvant Radiotherapy
metastasis
surgery
Disease-Free Survival
Survivors
grade
therapy
Neoplasms
tumors
cancer
Neoplasm Metastasis

Keywords

  • 5-Fluorouracil
  • Adjuvant therapy
  • Biliary cancer
  • Radiotherapy
  • Surgical resection

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma. / Nelson, John W.; Ghafoori, A. Paiman; Willett, Christopher G.; Tyler, Douglas; Pappas, Theodore N.; Clary, Bryan M.; Hurwitz, Herbert I.; Bendell, Johanna C.; Morse, Michael A.; Clough, Robert W.; Czito, Brian G.

In: International Journal of Radiation Oncology Biology Physics, Vol. 73, No. 1, 01.01.2009, p. 148-153.

Research output: Contribution to journalArticle

Nelson, JW, Ghafoori, AP, Willett, CG, Tyler, D, Pappas, TN, Clary, BM, Hurwitz, HI, Bendell, JC, Morse, MA, Clough, RW & Czito, BG 2009, 'Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma', International Journal of Radiation Oncology Biology Physics, vol. 73, no. 1, pp. 148-153. https://doi.org/10.1016/j.ijrobp.2008.07.008
Nelson, John W. ; Ghafoori, A. Paiman ; Willett, Christopher G. ; Tyler, Douglas ; Pappas, Theodore N. ; Clary, Bryan M. ; Hurwitz, Herbert I. ; Bendell, Johanna C. ; Morse, Michael A. ; Clough, Robert W. ; Czito, Brian G. / Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 73, No. 1. pp. 148-153.
@article{e512e30a225940fb9015bd012a4b66a3,
title = "Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma",
abstract = "Purpose: Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. Methods and Materials: A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors. Results: Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33{\%}, 37{\%}, 42{\%}, and 78{\%}, respectively. The median survival was 34 months. No patient died perioperatively. Patient age ≤60 years and perineural involvement adversely affected survival on univariate analysis. Patients undergoing R0 resection had a significantly improved rate of local control but no survival advantage. Despite having more advanced disease at presentation, patients treated neoadjuvantly had a longer survival (5-year survival 53{\%} vs. 23{\%}, p = 0.16) and similar rates of Grade 2-3 surgical morbidity (16{\%} vs. 33{\%}, p = 0.24) compared with those treated in the postoperative setting. Conclusion: These study results suggest a possible local control benefit from chemoradiotherapy combined with surgery in patients with advanced, resected biliary cancer. Furthermore, our results suggest that a treatment strategy that includes preoperative chemoradiotherapy might result in improved tumor resectability with similar surgical morbidity compared with patients treated postoperatively, as well as potentially improved survival outcomes. Distant failure remains a significant failure pattern, suggesting the need for more effective systemic therapy.",
keywords = "5-Fluorouracil, Adjuvant therapy, Biliary cancer, Radiotherapy, Surgical resection",
author = "Nelson, {John W.} and Ghafoori, {A. Paiman} and Willett, {Christopher G.} and Douglas Tyler and Pappas, {Theodore N.} and Clary, {Bryan M.} and Hurwitz, {Herbert I.} and Bendell, {Johanna C.} and Morse, {Michael A.} and Clough, {Robert W.} and Czito, {Brian G.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2008.07.008",
language = "English (US)",
volume = "73",
pages = "148--153",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Concurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma

AU - Nelson, John W.

AU - Ghafoori, A. Paiman

AU - Willett, Christopher G.

AU - Tyler, Douglas

AU - Pappas, Theodore N.

AU - Clary, Bryan M.

AU - Hurwitz, Herbert I.

AU - Bendell, Johanna C.

AU - Morse, Michael A.

AU - Clough, Robert W.

AU - Czito, Brian G.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Purpose: Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. Methods and Materials: A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors. Results: Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age ≤60 years and perineural involvement adversely affected survival on univariate analysis. Patients undergoing R0 resection had a significantly improved rate of local control but no survival advantage. Despite having more advanced disease at presentation, patients treated neoadjuvantly had a longer survival (5-year survival 53% vs. 23%, p = 0.16) and similar rates of Grade 2-3 surgical morbidity (16% vs. 33%, p = 0.24) compared with those treated in the postoperative setting. Conclusion: These study results suggest a possible local control benefit from chemoradiotherapy combined with surgery in patients with advanced, resected biliary cancer. Furthermore, our results suggest that a treatment strategy that includes preoperative chemoradiotherapy might result in improved tumor resectability with similar surgical morbidity compared with patients treated postoperatively, as well as potentially improved survival outcomes. Distant failure remains a significant failure pattern, suggesting the need for more effective systemic therapy.

AB - Purpose: Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. Methods and Materials: A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors. Results: Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age ≤60 years and perineural involvement adversely affected survival on univariate analysis. Patients undergoing R0 resection had a significantly improved rate of local control but no survival advantage. Despite having more advanced disease at presentation, patients treated neoadjuvantly had a longer survival (5-year survival 53% vs. 23%, p = 0.16) and similar rates of Grade 2-3 surgical morbidity (16% vs. 33%, p = 0.24) compared with those treated in the postoperative setting. Conclusion: These study results suggest a possible local control benefit from chemoradiotherapy combined with surgery in patients with advanced, resected biliary cancer. Furthermore, our results suggest that a treatment strategy that includes preoperative chemoradiotherapy might result in improved tumor resectability with similar surgical morbidity compared with patients treated postoperatively, as well as potentially improved survival outcomes. Distant failure remains a significant failure pattern, suggesting the need for more effective systemic therapy.

KW - 5-Fluorouracil

KW - Adjuvant therapy

KW - Biliary cancer

KW - Radiotherapy

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=57649102156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649102156&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.07.008

DO - 10.1016/j.ijrobp.2008.07.008

M3 - Article

VL - 73

SP - 148

EP - 153

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -